Invitation to 2cureX Webcast on August 25, 2022.

August 22 | 2022

2cureX will publish its Q2-report on Thursday, August 25, at 08:30 CET.

Fernando Andreu (CEO), Ole Thastrup (CSO) and Kenneth G. Johansen (CFO) will host a Webcast on Thursday, August 25, at 13:00 CET presenting the results and activities of the second quarter of 2022.

At the end of the presentation there will be a Q&A session.

Access the Live event on Thursday, August 25, at 13:00 CET using the following link: https://www.2curex.com/2curex-webinar-q2-2022/

Best regards
2cureX

About 2cureX

2cureX is a leader in cancer drug sensitivity testing and has developed the IndiTreat® (Individual Treatment) family of tests. Starting from a sample of the patient’s tumor, IndiTreat® creates thousands of 3D replicas (tumoroids) and predicts the tumor response to the different available drugs, providing the physician with valuable information to make the treatment decisions.

The first three IndiTreat® tests are aimed at optimizing treatment decisions in patients with metastatic colorectal cancer (IndiTreat® Start for first line of therapy, IndiTreat® Extend and Explore for third line). Additional tests are under development to cover other stages of colorectal cancer as well as other gastrointestinal cancers.

According to several reports, the total yearly expenditure in cancer-related In Vitro Diagnostic (IVD) tests exceeds 17.5Bn USD worldwide, from which 2.5 Bn USD are tests directly related to therapy decision making, with a CAGR of 12.7%. Despite this, only one third of all cancer treatments are supported by one of these tests. IndiTreat® aims at filling this gap and making Precision Oncology available to all cancer patients.

The company is listed on Nasdaq First North Growth Market in Stockholm (symbol: "2CUREX"). For more information about 2cureX visit www.2cureX.com

Certified Adviser: Redeye AB, +46 8 121 576 90, certifiedadviser@redeye.se